TheChek News Flow

Excellency (Palo Alto, CA) is developing a novel class called trifunctional Effector Cell Response Inhibitors (ECRIs) — lead asset Exl-111 is a trifunctional ECRI targeting the IgE axis, currently in Phase 1. Total consideration is up to $2bn in upfront + milestones; close expected H2 2026 subject to regulatory approvals.

The deal follows Novartis's agreement last week to acquire a breast-cancer candidate from Synnovation Therapeutics for up to $3bn — a clear pattern of dealmaking to fill the pipeline and offset patent expirations. The food allergy / immunology space is now a declared strategic priority for Basel.

This is unambiguously positive for DBV and here's why:

1. Strategic validation of food allergy at Phase 1 = $2bn Novartis just paid up to $2bn for a Phase 1 asset in food allergy. DBV has a Phase 3-proven asset (VITESSE positive Dec 2025) with a BLA coming in H1 2026. The implied risk-adjusted premium on DBV's VIASKIN® is enormous by comparison. This deal puts a floor — and arguably a ceiling test — on what a validated late-stage peanut allergy platform should be worth to a large pharma acquirer.

2. IgE axis = direct competitive + validation overlap Exl-111 is designed to disarm allergic effector cells at the source of activation by targeting the IgE axis. DBV's VIASKIN® patch works via epicutaneous immunotherapy and also modulates the IgE-mediated allergic response in peanut-allergic children. These are mechanistically adjacent — meaning Novartis just validated the target biology DBV is attacking.

3. Competitive landscape — important nuance Exl-111 is Phase 1 with a distinct mechanism (small molecule-like effector cell inhibition vs. DBV's antigen desensitization). They are potentially complementary rather than directly competitive — different treatment paradigms (inhibit mast cell activation vs. build tolerance). DBV retains the only late-stage patch desensitization approach.

4. M&A re-rating catalyst for DBV The Novartis move joins Sanofi/Regeneron's Dupixent (eosinophilic/atopic axis), AZ's Tezspire, and now this ECRI deal — all underscoring Big Pharma's appetite for allergy immunology. DBV is the only de-risked, BLA-ready peanut allergy asset not yet partnered. M&A optionality on DBV should re-rate after today.

Reported yesterday (March 26) — board-approved figures:

Cash trajectory: $276.2m in net financing inflows in 2025, driven by the PIPE and ATM. An additional $94m from warrant exercises landed in January 2026 — total liquidity now funds operations into Q2 2027.

The R&D step-up is strategic, not wasteful: $16.1m of the R&D increase was pre-commercial inventory build for VIASKIN® Peanut Patch ahead of a potential approval, and $6.9m went to the COMFORT Toddlers safety study enrollment. DBV is spending like a company preparing for launch — not burning capital aimlessly.

2026 Catalysts: BLA submission for 4-7 year olds H1 2026 (Priority Review eligible); BLA submission for 1-3 year olds H2 2026 under Accelerated Approval Pathway; COMFORT Toddlers topline readout expected.

The Novartis/Excellergy deal is the most important external read-across for DBV in months. A Big Pharma paying $2bn for a Phase 1 IgE-axis allergy asset on the same day DBV publishes solid balance sheet numbers ($288m effective cash runway into 2027) and confirms imminent BLA filing is close to a perfect storm of re-rating catalysts. The M&A angle in your Courchevel Fiche Biotech on DBV looks even more prescient today.